Nanolattix T320 Anti-Cancer Drug Granted U.S. Patent!
Release time:
2025-09-01
Recently, Nanolattix independently developed T320-ADC drug, “Humanized Anti-Tissue Factor Antibody, Antibody-Drug Conjugate Prepared Therefrom and Use Thereof,” passed the examination by the United States Patent and Trademark Office (USPTO) on August 5 and was officially granted a U.S. invention patent (Patent No.: US 12,377,160 B2). This marks the accelerated internationalization of Nanolattix T320 drug.
T320-ADC is one of Nanolattix core pipelines under development, targeting various malignant solid tumors such as cervical cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer.
Previously, it successively obtained clinical trial approvals for new drugs from China’s NMPA, the U.S. FDA, and Australia’s TGA. It is the first Class 1 biologics new drug in Shanxi Province to receive approval for clinical trials in multiple countries. Phase I clinical trials are being conducted in collaboration with several medical institutions, including the Cancer Hospital of the Chinese Academy of Medical Sciences, Shanxi Cancer Hospital, and Hunan Cancer Hospital.
To date, T320 has been granted invention patents in China, the United States, and Australia. Additionally, under the PCT (Patent Cooperation Treaty), patents in six regions or countries, including the European Union and the United Kingdom, have been accepted.
This grant represents significant international recognition of Nanolattix innovative R&D capabilities in the ADC field. It establishes crucial intellectual property protection for the development and commercialization of T320-ADC in the United States and potential global markets, marking another solid step forward in Nanolattix globalization strategy.
Tag:
recommend News
Share
